LONDON Dec 3 GlaxoSmithKline expects to
have pivotal clinical trial results on up to 14 medicines in the
next two years, including two new products which - if they work
- could change the way cancer and heart disease are treated.
Unveiling the next wave of its pipeline on Monday, Britain's
biggest drugmaker said it was now developing a broader range of
drugs than in the past, as it moves away from the industry's
traditional focus on "blockbusters".
Some of the new medicines will be relatively small
commercially but a handful have the potential to become
GSK is banking on the pipeline to revive its business after
it failed to grow sales this year as hoped, due to steep
pressure on drug prices in austerity-hit Europe.
Key experimental drugs that will have results from
final-stage Phase III clinical trials in 2013 and 2014 include
the heart drug darapladib and therapeutic cancer vaccine
MAGE-A3, the company said in a briefing to investors and
Chief Executive Andrew Witty said he did not expect any
significant increase in costs as a result of the roll out of new
products and GSK would continue to look for ways to increase
efficiency across the business.